The U.S. Food and Drug Administration approved albiglutide for treatment of adult type 2 diabetes in mid-April, 2014. It will be sold in the U.S. as Tanzeum. It’s a once-a-week subcutaneous injection.
Albiglutide is a GLP-1 receptor agonist, joining exenatide and liraglutide in that class.
It’s not a first-line drug for diabetes. In clinical studies, it’s been used alone and with metformin, glimiperide (a sulfonylurea), pioglitazone, and insulin.
The most frequent side effects have been upper respiratory infections, diarrhea, nausea, and injection site reactions.